Urbanetz Nora Anne, Lippold Bernhard Christian
Institut für Pharmazeutische Technologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
Eur J Pharm Biopharm. 2005 Jan;59(1):107-18. doi: 10.1016/j.ejpb.2004.08.005.
The incorporation of a drug in a carrier by melt embedding may either result in a solid solution or in a solid suspension of the active ingredient within the carrier material. As the dispersivity of the drug is of outstanding importance for its dissolution characteristics, parameters which are supposed to influence crystallinity and dispersivity, e.g. cooling rate during preparation and storage conditions like temperature and relative humidity are investigated. It is found that the absence of crystalline drug material in solid dispersions containing nimodipine and polyethylene glycol 2000 is the prerequisite for a high dissolution rate and a remarkable supersaturation in the dissolution medium. Shock freezing during the preparation process, low storage temperatures and low relative humidities are identified to prevent recrystallisation. Furthermore, emphasis is put on the physico-chemical characterisation of solid dispersions. It is shown that the determination of crystallinity and dispersivity of the drug in solid dispersions can only be successful by combining different investigation methods like differential scanning calorimetry, hot stage microscopy, X-ray diffraction as well as macroscopic observation.
通过熔融包埋将药物掺入载体中可能会形成固溶体,或者使活性成分在载体材料中形成固体悬浮液。由于药物的分散性对其溶解特性至关重要,因此研究了一些可能影响结晶度和分散性的参数,例如制备过程中的冷却速率以及储存条件(如温度和相对湿度)。研究发现,在含有尼莫地平和聚乙二醇2000的固体分散体中不存在结晶药物材料是实现高溶解速率和在溶解介质中显著过饱和的前提条件。制备过程中的快速冷冻、低储存温度和低相对湿度可防止重结晶。此外,重点是对固体分散体进行物理化学表征。结果表明,只有通过结合差示扫描量热法、热台显微镜、X射线衍射以及宏观观察等不同的研究方法,才能成功测定固体分散体中药物的结晶度和分散性。